Mareye Voortman1, Daan Fritz, Oscar J M Vogels, Filip Eftimov, Diederik van de Beek, Matthijs C Brouwer, Marjolein Drent. 1. aDepartment of Pulmonology, ILD Center of Excellence, St. Antonius Hospital, Nieuwegein bDivision of Heart & Lungs, Department of Pulmonology, University Medical Centre Utrecht, Utrecht cDepartment of Neurology, Academic Medical Centre, University of Amsterdam, Amsterdam Neuroscience, Amsterdam dDepartment of Neurology, ILD Center of Excellence, St. Antonius Hospital, Nieuwegein eDepartment of Pharmacology and Toxicology, FHML, Maastricht University, Maastricht, The Netherlands.
Abstract
PURPOSE OF REVIEW: To discuss cause, clinical manifestations, diagnostics, and treatment of small fiber neuropathy (SFN). The diagnosis is difficult and can be easily missed. RECENT FINDINGS: SFN causes high morbidity with disabling symptoms and impact on quality of life. Patients may benefit from being diagnosed with SFN, even if no underlying cause is identified and no specific treatment is yet available. Recently, genetic mutations as a possible cause of SFN were identified. Clinical diagnostic criteria have been proposed, but no gold standard exists, and each test has its limitations. The diagnosis requires a combination of typical symptoms, abnormal neurologic findings, and absence of large fiber involvement. Clinicians should be aware of overlapping symptoms of SFN and fibromyalgia. Treatment is often difficult, even when the underlying cause is identified and appropriately treated. Usually, only symptomatic relief of complaints is available. SUMMARY: Awareness of SFN and related symptoms is of great clinical relevance. Guidelines for appropriate diagnostic workup using a stepwise approach involving a combination of tests are warranted. Even if no treatment is available, patients may benefit from timely recognition of SFN.
PURPOSE OF REVIEW: To discuss cause, clinical manifestations, diagnostics, and treatment of small fiber neuropathy (SFN). The diagnosis is difficult and can be easily missed. RECENT FINDINGS:SFN causes high morbidity with disabling symptoms and impact on quality of life. Patients may benefit from being diagnosed with SFN, even if no underlying cause is identified and no specific treatment is yet available. Recently, genetic mutations as a possible cause of SFN were identified. Clinical diagnostic criteria have been proposed, but no gold standard exists, and each test has its limitations. The diagnosis requires a combination of typical symptoms, abnormal neurologic findings, and absence of large fiber involvement. Clinicians should be aware of overlapping symptoms of SFN and fibromyalgia. Treatment is often difficult, even when the underlying cause is identified and appropriately treated. Usually, only symptomatic relief of complaints is available. SUMMARY: Awareness of SFN and related symptoms is of great clinical relevance. Guidelines for appropriate diagnostic workup using a stepwise approach involving a combination of tests are warranted. Even if no treatment is available, patients may benefit from timely recognition of SFN.
Authors: Ting Bao; Andrew D Seidman; Lauren Piulson; Emily Vertosick; Xi Chen; Andrew J Vickers; Victoria S Blinder; Wanqing I Zhi; Qing Li; Linda T Vahdat; Maura N Dickler; Mark E Robson; Jun J Mao Journal: Eur J Cancer Date: 2018-07-13 Impact factor: 9.162
Authors: Mareye Voortman; Jolanda De Vries; Celine M R Hendriks; Marjon D P Elfferich; Petal A H M Wijnen; Marjolein Drent Journal: Sarcoidosis Vasc Diffuse Lung Dis Date: 2019-05-01 Impact factor: 0.670
Authors: M Voortman; C M R Hendriks; M D P Elfferich; F Bonella; J Møller; J De Vries; U Costabel; M Drent Journal: Lung Date: 2019-02-16 Impact factor: 2.584
Authors: Michael Brines; Daniel A Culver; Maryam Ferdousi; Martijn R Tannemaat; Monique van Velzen; Albert Dahan; Rayaz A Malik Journal: Sci Rep Date: 2018-03-16 Impact factor: 4.379